Alcon (ALC) terminated its definitive merger agreement with Staar Surgical Company (STAA) announced on August 5, 2025. “Throughout this process we remained disciplined with our views on price and risk. Moving forward, our refractive strategy is unchanged and our new wavelight plus offering remains our focus for the most popular refractive surgery in the world, LASIK. This will be an exciting year for Alcon as we continue the global launches of more than 10 major products in both our surgical and vision care franchises. These innovations substantively advance outcomes for eye care disorders and help patients around the world see brilliantly,” said David J. Endicott, CEO of Alcon.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Midday Fly By: Nvidia launches Rubin platform, Vistra to acquire Cogentrix
- Broadwood ‘thanks’ Staar Surgical shareholders for rejecting Alcon transaction
- BTIG sees ‘limited reason to want to own’ Staar Surgical until clarity emerges
- Staar Surgical to terminate Alcon merger agreement
- Broadwood ‘denounces’ STAAR Surgical’s fouth dely of shareholder vote